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Abstract
Background
The interaction between smoking and the use of antiplatelet agents on the prognosis of
vasospastic angina (VA) is rarely investigated.
Methods
VA-Korea is a nation-wide multi-center registry with prospective design (n = 1812). The pri-
mary endpoint was the composite occurrence of acute coronary syndrome (ACS), symp-
tomatic arrhythmia, and cardiac death. Log-rank test and Cox proportional hazard model
were for statistical analysis. Also, we conducted interaction analysis in both additive and
multiplicative scales between smoking and antiplatelet agents among VA patients. For addi-
tive scale interaction, relative excess risk due to interaction (RERI) was calculated and for
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multiplicative scale interaction, the ratio of hazard ratio (HR) was calculated. All statistical
analysis conducted by Stata Ver 16.1.
Results
Patients who were smoking and using antiplatelet agents had the highest incidence rate in
the primary composite outcome. The incidence rate was 3.49 per 1,000 person-month (95%
CI: 2.30-5.30, log-rank test for primary outcome p = 0.017) and HR of smoking and using
antiplatelet agents was 1.66 (95%CI: 0.98-2.81). The adjusted RERI of smoking and using
antiplatelet agents was 1.10 (p = 0.009), and the adjusted ratio of HR of smoking and using
antiplatelet agents was 3.32 (p = 0.019). The current study observed the interaction
between smoking and using antiplatelet agents in both additive and multiplicative scales.
Conclusions
Smoking was associated with higher rates of unfavorable clinical outcomes among VA
patients taking antiplatelet agents. This suggested that VA patients, especially those using
antiplatelet agents should quit smoking.
Introduction
The prognosis of vasospastic angina (VA) is known to be better than acute coronary syndrome
(ACS). Previous studies showed that angina at rest, ST-segment elevation during angina, coro-
nary arterial stenosis were linked with worse prognosis among VA patients [1, 2]. Antiplatelet
agents have been used for primary prevention of cardiovascular disease among high risk
patients of coronary artery disease (CAD) like diabetes [3]. Antiplatelet agents are usually pre-
scribed for secondary prevention for those with combined atherosclerotic CAD or receiving
percutaneous coronary intervention (PCI) in VA patients. However, the use of antiplatelet
agents, even low dose aspirin, showed controversial results on the prognosis of patients with
VA [4–7]. Several studies argued that the use of aspirin might be linked to unfavorable progno-
sis, but others disputed that [4–7].
Smoking is the well-known risk factor for developing vasospasm [8], and can lead to poor
clinical outcomes in VA patients [9–11], as well as an established risk for atherosclerotic CAD
[12]. Smokers in VA patients who had risk factors or established CAD, particularly those with
coronary stents, were likely to take antiplatelet agents. So the relationship between smoking
and the use of antiplatelet agents in VA patients need to be sought. Smoking can influence
platelet functions [13], and can inhibit the activity of antiplatelet agents [14, 15].
In this regard, the impact of smoking on the prognosis of VA patients who are taking anti-
platelet agents should be investigated. However, as far as we know, no previous study has yet
explored the interaction of antiplatelet agents and smoking on the prognosis in those with VA.
Interaction analysis, both additive and multiplicative scales of interaction which theoretical
epidemiologists recommend, could estimate this relationship of those in VA patients [16, 17].
Thus, this study aims to explore the interaction of smoking and antiplatelet agents on the prog-
nosis of VA.
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Methods
Participants
VA-Korea (Variant angina Korea) is a nation-wide prospective cohort based on the multi-cen-
ter registry. The registry enrolled patients who had chest pain suggesting of VA and undertak-
ing CAG and an ergonovine (EG) provocation test. Patients with aged 18 or over were
candidates. Patients who had catheter-induced spasm during CAG, malignancy, end-stage
renal disease, or inflammatory disease were excluded.
A total of 2960 patients were enrolled from May 2010 to June 2015 in 11 tertiary hospitals
in Korea. One thousand eight hundred ninety-two patients (n = 1892) had positive results
(680 definite and 1212 intermediate) in their provocation tests. Definite spasm is defined as
total or subtotal (>90% luminal diameter narrowing) occlusion of coronary artery accompa-
nied by ischemic symptoms and/or electrocardiographic (ECG) changes, and intermediate
spams define as 50% to 90% luminal narrowing with or without ischemic symptoms and/or
ECG changes during provocation test [18]. One thousand eight hundred thirty-eight (1838)
patients followed the study and 54 patients were lost during the follow-up period. Information
on both smoking status and use of antiplatelet agents were not gathered among 26 participants.
In the final analysis, 1812 patients were included. Patients with positive EG provocation test
results and spontaneous vasospasm received medical treatment, including calcium channel
blockers and other vasodilators during follow-up. Patients were divided into four groups
according to their differing use of smoking and antiplatelet agents at the enrollment of study:
non-smoker and no-antiplatelet agents, smoking only, antiplatelet agents only, and both
smoking and antiplatelet agents. Participants were followed up for three years and investigated
during this time for clinical events.
Among the study participants, 820 patients were taking antiplatelet agents. Six hundred
and thirty four (634) patients took aspirin, 56 patients were taking clopidogrel, and 130
patients took both aspirin and clopidogrel.
The study protocol was approved by the ethical review board of Hallym University Hospital
(Hallym University Hospital IRB: No. 2010-I007) and each participating hospital. All proce-
dures and methods were undertaken in accordance with the ethical guidelines of each hospital.
Written informed consent was given to all participants of the study.
Primary endpoints
The primary composite endpoints were death from cardiac causes, acute coronary syndrome
(ACS), and new-onset symptomatic arrhythmia during the 3-year follow-up. ACS was defined
as continuous or recurrent ischemic chest pain lasting more than 20 minutes with evidence of
ischemic ECG changes and/or increase of cardiac markers, including myocardial infarction.
Ischemic ECG changes were defined as followings: an ST elevation (0.1 mV or more), an ST
depression (0.1 mV or more), a T-wave inversion, or a new occurrence of left bundle branch
block (LBBB), which were recorded in at least two contiguous leads on the 12-lead ECG [19–
21]. Symptomatic arrhythmia is defined as new-onset symptomatic premature beats, atrioven-
tricular block, sick-sinus rhythm, atrial or ventricular tachycardia/fibrillation [22]. ECG was
regularly checked during the outpatient follow-up and during emergency visits. When patients
had symptoms related to arrhythmia, 24 hour Holter monitoring was undertaken. All adverse
events of interest were confirmed through source document review, including medical records
as well as telephone interviews were adjudicated by the local events committee.
Detailed procedures on coronary angiography, ergonovine provocation test and interpreta-
tion of ergonovine provocation test results were reported previously [7].
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Statistical analysis
For continuous variables, means and standard deviations were presented, and the differences
of means between the groups were examined by the analysis of variance (ANOVA). For cate-
gorical variables, numbers and proportions were demonstrated, and chi-square tests were car-
ried out. Each incidence rates and 95% confidence interval (CI)s were demonstrated according
to both the use of antiplatelet agents and current smoking. Events per 1,000 person month
were demonstrated for estimating the incidence rate of the primary endpoint (ACS, arrhyth-
mia, or cardiac death). The log-rank test was conducted to compare the survival difference
among 4 groups by the use of antiplatelet agents and smoking status. In addition, Cox propor-
tional hazard regression was conducted to estimate the survival difference among groups
using antiplatelet agents and smoking status. The HRs and the 95% CIs were presented. For
the interaction analysis, post-estimation commands of Stata were utilized after conducting
Cox proportional hazard regression. Linear combination command was used for ratios of HR,
and nonlinear combination command was used for relative excess risk due to interaction
(RERI). When p was less than 0.05, it was considered statistically significant. Statistical analysis
was conducted by Stata ver. 16.1 (Stata Corp, College Station, Texas).
Interaction analysis by additive scale and multiplicative scale
We followed the recommendation of theoretical epidemiologists. When the interaction analy-
sis is conducted, the recommendation encourages both additive scale and multiplicative scale
to provide sufficient information on interaction [16, 17].
RERI can be estimated by the following formula.
RERI = HR combination of smoking and antiplatelet agents – HR only smoking – HR only
antiplatelet agents + 1
When RERI is larger than 0, It indicates that there is a supra-additive interaction.
Ratio of HR is estimated by the following formula.
Ratio of HR = HR combination of smoking and antiplatelet agents / (HR only smoking �
HR only antiplatelet agents)
When ratio is larger than 1, It indicates that a combined effect is larger than the product of
the two separate effects.
Results
Baseline demographic and clinical characteristics of study participants
Demographic and clinical characteristics were presented in Table 1. Total study population
was 1812. The number of 4 groups are as follows: 742 were in non-smoking and no use of anti-
platelet agents group, 250 in smoking and no use of antiplatelet agents group, 568 in non-
smoking and use of antiplatelet agents group, and 252 in both smoking and using of antiplate-
let agents group. Mean age ranged from 49.7 to 59 years (with differences in each group). Par-
ticipants’ ages were higher among non-smokers. Sex, past medical history of hypertension,
diabetes, coronary heart disease (CHD), percutaneous coronary intervention (PCI) history,
spasm severity, and presence of atherosclerosis were statistically different among the groups by
smoking and using antiplatelet agents. Percentages of male were higher among smokers. Medi-
cal history of diabetes mellitus, coronary heart disease (CHD), percutaneous coronary inter-
vention (PCI) were highest among the group with both smoking and using antiplatelet agents.
Percentage of definite spasm and atherosclerosis at angiography were the highest among the
groups with smoking and using antiplatelet agents. Lipid profiles were statistically different
among groups. In particular, high-density lipoprotein cholesterol (HDL-C) levels were lower,
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and triglyceride levels were higher in smokers. In general, unfavorable basal clinical conditions
were observed among patients who were smoking and using antiplatelet agents.
Incidence rate of primary composite outcome and its’ subcomponents
Primary endpoints were the composite of occurrence of cardiac death, acute coronary syn-
drome (ACS), and new-onset symptomatic arrhythmia during a 3-year follow-up. Incidence
rates and unadjusted HRs for the composite primary endpoint and its’ subcomponents are
presented in Table 2.
The incidence rate of the primary composite outcome was higher in patients who were
smoking and using antiplatelet agents; 3.49 per 1,000 person-month (95% CI: 2.30-5.30, log-
rank test for primary outcome p = 0.017) and the HR of smoking and using antiplatelet agents
was 1.66 (95%CI: 0.98-2.81). The incidence rate of new-onset symptomatic arrhythmia showed
a higher trend in the group with smoking and using the antiplatelet agents. It was 1.04 per
1,000 person-month (95%CI: 0.49-2.17, log-rank test for arrhythmia p = 0.394), and the HR
was 2.16 (95% CI: 0.78-5.96). However, there was not a statistical difference. Similarly, the inci-
dence rate of ACS showed the trend of being highest in the group smoking and using antiplate-
let agents, with 2.26 per 1,000 person-month (95% CI:1.36–3.75, log-rank test for ACS
p = 0.092) and HR was 1.57 (95% CI:0.82-3.02). When it comes to cardiac death, we could not
Table 1. Basal demographic and clinical characteristics of study participants by smoking and use antiplatelet agent.
Smoking (-) & AntiPLTs (-) Smoking (+) & AntiPLTs
(-)
Smoking (-) & AntiPLTs
(+)
Smoking (+) & AntiPLTs
(+)
n = 742 n = 250 n = 568 n = 252
Mean sd Mean sd Mean sd Mean sd p
Age 54.71 11.21 49.67 10.88 58.96 10.97 52.82 10.07 <0.001
BMI 28.78 91.44 24.81 3.74 30.04 105.94 24.55 3.06 0.765
SBP 126.69 44.15 126.03 19.60 125.82 18.92 129.53 19.05 0.471
DBP 76.74 11.68 78.32 12.24 75.55 12.63 79.71 12.61 <0.001
Total cholesterol 175.00 36.33 180.58 34.32 170.76 37.13 172.78 35.14 0.006
TG 131.55 93.98 175.88 119.78 130.27 83.97 176.84 145.37 <0.001
HDL-C 47.70 12.96 44.56 10.97 47.58 12.66 44.30 14.10 <0.001
LDL-C 104.48 30.85 106.90 31.80 102.71 32.22 99.87 30.72 0.107
hsCRP 0.73 4.24 1.68 11.42 0.79 7.80 0.53 1.49 0.313
CKMB 4.67 11.82 8.23 44.59 5.52 19.46 7.66 25.92 0.218
Troponin-I 0.32 2.92 0.30 1.59 1.00 6.77 0.63 2.97 0.232
LV-EF 64.69 6.68 64.44 5.97 64.23 6.72 64.21 7.14 0.637
n percent n percent n percent n percent
Sex (male) 350 47.17 226 90.4 306 53.87 239 94.84 <0.001
HTN 241 32.48 70 28.00 276 48.59 99 39.44 <0.001
DM 58 7.82 20 8.03 61 10.76 33 13.15 0.046
Dyslipidemia 119 16.04 40 16.06 90 15.96 49 19.60 0.570
CHD 73 9.84 14 5.62 98 17.28 35 13.94 <0.001
PCI 6 0.81 1 0.40 22 3.87 10 3.97 <0.001
Definite spasm 218 29.38 103 41.20 215 37.85 128 50.79 <0.001
Atherosclerosis > 50% 25 3.37 10 4.00 63 11.09 35 13.89 <0.001
antiPLT, antiplatelet agents; sd, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, Triglyceride; HDL-C, high-
density lipoprotein cholesterol; LDL-C; low-density lipoprotein cholesterol; hs-CRP; high sensitivity C-reactive protein; CK-MB; creatine kinase-MB; LV-EF, left
ventricular ejection fraction; HTN, hypertension; DM, diabetes mellitus; CHD, coronary heart disease; PCI, percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0248386.t001
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find statistically significant differences in incidence rates and HRs among groups by smoking
and using antiplatelet agents.
Interaction analysis of smoking and use of antiplatelet agents
Table 3 showed the interaction between smoking and the use of antiplatelet agents on the pri-
mary endpoint.
Table 2. Incidence rates and HRs (by uni-variable Cox-proportional hazard model) for primary outcome and sub-components.
no event (%) Person-month rate 95% CI p� HR 95% CI p
Primary outcome 0.017
Smoking(-) & AntiPLTs(-) 742 37 15497.59 2.39 1.73 3.30 ref
Smoking(+) & AniPLTs(-) 250 7 5535.57 1.26 0.60 2.65 0.56 0.25 1.25 0.154
Smoking(-) & AniPLTs(+) 568 23 13940.17 1.65 1.10 2.48 0.77 0.46 1.30 0.332
Smoking(+) & AniPLTs(+) 252 22 6305.74 3.49 2.30 5.30 1.66 0.98 2.81 0.060
Arrhythmia 0.394
Smoking(-) & AntiPLTs(-) 742 8 16240.16 0.49 0.25 0.99 ref
Smoking(+) & AniPLTs(-) 250 3 5681.41 0.53 0.17 1.64 1.10 0.29 4.16 0.884
Smoking(-) & AniPLTs(+) 568 7 14432.23 0.49 0.23 1.02 1.01 0.37 2.79 0.980
Smoking(+) & AniPLTs(+) 252 7 6756.70 1.04 0.49 2.17 2.16 0.78 5.96 0.137
ACS 0.092
Smoking(-) & AntiPLTs(-) 742 23 16017.41 1.44 0.95 2.16 ref
Smoking(+) & AniPLTs(-) 250 5 5649.48 0.89 0.37 2.13 0.63 0.24 1.65 0.344
Smoking(-) & AniPLTs(+) 568 14 14380.81 0.97 0.58 1.64 0.68 0.35 1.33 0.264
Smoking(+) & AniPLTs(+) 252 15 6635.50 2.26 1.36 3.75 1.57 0.82 3.02 0.172
Cardiac death 0.205
Smoking(-) & AntiPLTs(-) 742 7 16386.04 0.43 0.20 0.90 ref
Smoking(+) & AniPLTs(-) 250 0 5733.26 0.00 . .
Smoking(-) & AniPLTs(+) 568 2 14570.84 0.14 0.03 0.55 0.33 0.07 1.57 0.162
Smoking(+) & AniPLTs(+) 252 3 6941.73 0.43 0.14 1.34 1.05 0.27 4.08 0.939
rate: event/1000 person-month, HR: hazard ratio; P�: p values of log-rank test; AntiPLTs: antiplatelet agents.
https://doi.org/10.1371/journal.pone.0248386.t002
Table 3. Interaction analysis of smoking and antiplatelet agents on primary composite outcome.
Smoking(-) Smoking(+) HR for smoking(-) vs smoking(+) within strata of
antiplatelet agents
HR(95% CI):p HR(95% CI):p HR(95% CI):p














Measure of interaction on additive scale: RERI 1.10(0.28-
1.92):0.009
Measure of interaction on multiplicative scale: ratio of HRs 3.32(1.21-
9.06):0.019
CI, confidence interval; RERI, relative excess risk due to Interaction; HR is adjusted for sex, age, BMI, history of coronary heart disease, hypertension, diabetes,
dyslipidemia, severity of spasm, severity of atherosclerosis; Ratios of HRs were estimated using the linear combination command, RERI was estimated using the
nonlinear combination command after cox proportional hazard regressions (linear combination and nonlinear combination are post-estimation commands of Stata).
https://doi.org/10.1371/journal.pone.0248386.t003
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Table 3 and Fig 1 showed the interaction of smoking and antiplatelet agents on the progno-
sis. In this model, age, sex, BMI, history of coronary heart disease, history of hypertension, his-
tory of diabetes, history of dyslipidemia, severity of atherosclerosis, and severity of spasm were
included. Adjusted HR was 1.42 (95% CI: 078-2.57). RERI was 1.10 (95%CI:0.28-1.92) and the
ratio of HR was 3.32 (95%CI:1.21-9.06). This study observed both a supra-additive interaction
and a supra-multiplicative interaction between smoking and the using of antiplatelet agents on
the primary outcome.
Table 4 demonstrated the result of interaction analysis when additional covariates were
included in the model.
Total cholesterol, triglyceride, and HDL-cholesterol were additionally included in the
model. In this model, RERI was 0.88 (95%CI:-0.27-2.03; p = 0.136) and the ratio of HR was
2.06 (95%CI: 0.70-6.37; p = 0.198). RERI was larger than 0 and the ratio of HR was larger than
1. However, the amplitudes of both RERI and the HR ratio decreased, and we did not observe
statistical significance.
Fig 1. Interaction of smoking and antiplatelet agents on the primary composite outcome. RERI: relative risk of relative excess risk due to interaction, HR: hazard
ratio.
https://doi.org/10.1371/journal.pone.0248386.g001
PLOS ONE Interaction of smoking and antiplatelet agents on prognosis of vasospastic angina
PLOS ONE | https://doi.org/10.1371/journal.pone.0248386 April 2, 2021 7 / 12
Discussion
To the best knowledge, the current study may be the first study to investigate the interaction
between smoking and antiplatelet agents on the prognosis of vasospastic angina following the
recommendation for interaction analysis by theoretical epidemiologists. The epidemiologists
recommended that researchers should measure in both additive scale and multiplicative scale
in order to provide sufficient information to readers [16, 17]. In this study, both supra-additive
and supra-multiplicative interactions were observed between smoking and using antiplatelet
agents. RERI was 1.10 (95%CI:0.28-1.92), and the ratio of HR was 3.32 (95%CI:1.21-9.06). It
implies that smoking can aggravate the prognosis of VA patients who were taking antiplatelet
agents and the interaction between smoking and antiplatelet agents may contribute this unfa-
vorable prognosis. Smoking is one of the most important modifiable risk factors of CAD. The
harmful effects of smoking can be attributed to many pathophysiologic changes including,
hemodynamic change of systemic vasculature and coronary artery, inflammation, oxidative
stress, endothelial dysfunction, unfavorable changes in lipid metabolism, hypercoagulative
state, thrombosis, and platelet aggregation [23–27]. Smoking also can induce coronary vaso-
spasm and worsens the prognosis of VA [11]. It has been yet controversial that the use of anti-
platelet agents can affect the prognosis among VA patients. Some studies reported worse
prognoses of VA in using low dose aspirin [4, 6]. In contrast, other studies observed that aspi-
rin was neutral [5, 7]. A study from Korea reported the interaction between using dual anti-
platelet agents and smoking on prognosis in the subgroup analysis [7]. It is unclear whether a
worse prognosis is related to the combined effect of antiplatelet agents and smoking per se or
unfavorable baseline conditions of patients who are using the antiplatelet agents. The result of
the current study suggests that cessation of smoking should be emphasized among VA patients
who are taking antiplatelet agents for a better prognosis.
Although we found the interaction of smoking and antiplatelet agents and its impact on the
prognosis of VA, this study could not investigate the more detailed mechanisms of the interac-
tion. We can presume that smoking might alter the hemodynamics of blood vessels, endothe-
lial function, platelet aggregation, thrombosis, and blood coagulation [24–26, 28–30], and this
resulted in the inference on functions of antiplatelet agents directly or indirectly [14, 15].
Table 4. Interaction analysis of antiplatelet agents and smoking on primary composite outcome additionally HDL cholesterol, TG, total cholesterol, and diastolic
blood pressure were adjusted.
Smoking(-) Smoking(+) HR for smoking(-) vs smoking(+) within strata of
antiplatelet agents
HR(95% CI):p HR(95% CI):p HR(95% CI):p














Measure of interaction on additive scale: RERI 0.88(-0.27-
2.03):0.136
Measure of interaction on multiplicative scale: ratio of HRs 2.06(0.70-
6.37):0.198
CI, confidence interval; RERI, relative excess risk due to Interaction; HR is adjusted variables for Table 3 sex, age, BMI, history of coronary heart disease, hypertension,
diabetes, dyslipidemia, severity of spasm, severity of atherosclerosis, total cholesterol, TG, and HDL Cholesterol; HRs and ratios of HRs were estimated using the linear
combination command, RERI was estimated using the nonlinear combination command after Cox proportional hazard regression (linear combination and nonlinear
combination are post-estimation commands of Stata).
https://doi.org/10.1371/journal.pone.0248386.t004
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Although no study examined the direct interaction between smoking and aspirin, some dem-
onstrated the clue in that aspirin could not overcome the more potent effect of smoking on
platelet aggregation and thrombosis [13, 31]. It implies the interaction might be present and
smoking could lead to platelet aggregation and thrombosis.
Another possible mechanism of interaction is general metabolic changes induced by smok-
ing particularly alteration of lipid metabolism [24]. Smokers have higher blood triglyceride lev-
els and a lower blood HDL-cholesterol levels [27]. As seen in the Table 4, when total
cholesterol, triglyceride, HDL-Cholesterol were additionally included in the model, the statisti-
cal significance of interactions was not seen in either additive scale or multiplicative scale.
RERI was 0.88 (95%CI:-0.27-2.03, P = 0.136) and ratio of HR was 2.06 (95%CI: 0.70-6.37,
P = 0.198). Thus, triglyceride and HDL-cholesterol might be contributors of interaction
between smoking and using of antiplatelet agents.
The observed interaction in the current study may be ascribed to unfavorable basal charac-
teristics of patients who were using antiplatelet agents. Usually, antiplatelet agents are pre-
scribed for primary and secondary prevention. As seen in Table 1, patients using antiplatelet
agents have higher prevalences of hypertension, diabetes, and CAD. Smoking might interact
with unfavorable basal conditions of antiplatelet users, and smoking could aggravate patients’
general conditions using the antiplatelet agents. Finally, we could not exclude the possibility
that residual confounders may affect the result. Although this study utilized multiple regres-
sion models to adjust potential confounders, observational studies cannot fully control residual
confounders by using the statistical models.
Strengths and limitations
The main strength of study has a larger number of study participants with multi-center
(n = 1812). The prospective cohort design is another strength of the study. Three aspects of
study limitations should be mentioned. The main limitation is that this study is an observa-
tional study. Observed results could not establish the causality due to residual confounders. In
particular, patients who were taking antiplatelet agents have unfavorable basal clinical condi-
tions. They had higher prevalences of hypertension, diabetes, and CAD. These unfavorable
basal conditions of VA patients taking antiplatelet agents may contribute the worse outcomes.
Secondly, this study could not explore more detailed mechanisms of the interaction between
smoking and antiplatelet agents. Thirdly, this study could not consider changes in smoking
and antiplatelet agent use because we gather the information on smoking and using of anti-
platelet agents at the point of enrollment. We hope that future studies investigate how smoking
changes metabolisms related to the interaction between smoking and the use of antiplatelet
agents, such as changes in platelet functions, thrombosis, functions of endothelium, and lipid
metabolisms.
Conclusions
We observed the interaction of smoking and antiplatelet agents on the prognosis of patients
with VA. The result of the current study indicated that smoking could lead to a worse progno-
sis of VA, particularly among those who were using antiplatelet agents. Interactions were
observed in both additive and multiplicative scales. Quitting smoking could not be overem-
phasized among Va patients for a better prognosis.
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